european biotech Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : european biotech

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dalroi who started this subject	12/20/2002 5:30:59 AM
From: nigel bates	Read Replies (1) of 108

Keeping the thread live... Novozymes A/S Sells Patents to Solvay BAGSVAERD, Denmark, Dec. 20 /PRNewswire/ -- As of 19 December 2002 Solvay (SOLbt.BR - Reuters) has acquired the patents related to the production of a recombinant enzyme for pharmaceutical specialities. Novozymes has retained the right to develop, manufacture and market the specific enzyme outside this field. Novozymes (NZYMb.CO - Reuters) will receive a minor up-front payment this year for disposal of the patents. If Solvay markets the specific enzyme covered by the patented technology, Novozymes is entitled to royalty payment based on the net sales. Long-term strategy The agreement highlights the breadth of Novozymes' strong patent portfolio within proteins and underlines Novozymes' strategy to commercialize and exploit ideas in which Novozymes' technologies can play a role. Outlook for 2002 The agreement will have a slightly positive impact on this year's operating profit. Novozymes A/S is a biotech-based world leader in enzymes and microorganisms for industrial use. Novozymes also applies its core competences in selected pharmaceutical areas. With headquarters in Denmark, Novozymes employs more than 3,500 people. Novozymes is represented in 25 countries and sells enzymes and microorganisms in more than 130 countries. The company's B-shares are listed on the Copenhagen Stock Exchange. For further company information, visit Novozymes on the Internet at: www.novozymes.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next